FAPI Uptake in Malignant Ascites: A Case Report

Pegah Sahafi; Mohammad Hadi Samadi; Zahra Fazeli; Ali Emadi-Torghabeh; Atena Aghaee

doi:10.1097/RLU.0000000000006003

FAPI Uptake in Malignant Ascites: A Case Report

Clin Nucl Med. 2025 Jun 5. doi: 10.1097/RLU.0000000000006003. Online ahead of print.

Authors

Pegah Sahafi¹, Mohammad Hadi Samadi¹, Zahra Fazeli¹, Ali Emadi-Torghabeh², Atena Aghaee¹

Affiliations

¹ Nuclear Medicine Research Center, Mashhad University of Medical Science, Mashhad, Iran.
² Solid Tumor Treatment Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

PMID: 40472273
DOI: 10.1097/RLU.0000000000006003

Abstract

We present a 69-year-old man with a history of renal cell carcinoma who previously underwent nephrectomy. He was referred to our department for 99mTc-FAPI and 99mTc-PSMA scans (under an investigational protocol) due to a newly diagnosed rising prostate-specific antigen (PSA) level and a suspected retroperitoneal mass of unknown origin. Notably, the patient had a known history of malignant ascites, and his 99mTc-FAPI scan demonstrated increased radiotracer uptake within the abdominal cavity.

Keywords: FAPI; fibroblast activation protein; malignant ascites; prostate cancer; renal cell carcinoma.